BackgroundGout flares are followed by transient major cardiovascular (CV) risk, implicating the role of inflammation; whether premature mortality in gout and CV risk is independent of serum urate (SU) and ASCVD risk factors is unknown.MethodsUsing serial US nationwide prospective cohorts, we evaluated the independent association of prevalent gout with all‐cause and CV mortality, adjusting for SU, ASCVD risk factors, comorbidities, medications, and kidney function and compared mortality between the early (1988‐1994 baseline) and late cohorts (2007‐2016 baseline). We replicated late cohort findings among incident gout in a nationwide UK cohort (2006‐2010 baseline).ResultsAdjusted hazard ratios (HRs) for mortality in prevalent gout were similar in early and late US cohorts (HR, 1.20; 1.03–1.40 and 1.19; 1.04–1.37, respectively); HRs with further adjustment for SU were 1.19 (1.02–1.38) and 1.19 (1.03–1.37), respectively. Adjusted HR among incident gout from the UK late cohort was 1.61 (1.47–1.75); these associations were larger among women (p for interaction=0.04) and prominent among Black individuals. Adjusted HR for CV mortality in the late US cohort was 1.39 (1.09–1.78); those for circulatory, cardiovascular, and coronary heart disease deaths among Britons with incident gout were 1.48 (1.24–1.76), 1.49 (1.20–1.85) and 1.59 (1.26–1.99), respectively.ConclusionsGout patients experience a persistent mortality gap in all‐cause and CV deaths, even adjusting for SU and ASCVD risk factors, supporting a role for gout‐specific pathways (e.g., flare inflammation). These findings suggest gaps in current care, pacricularly in women and possibly among Black patients.image